Enterprise Associates 14, L... Net Worth

The estimated Net Worth of Enterprise Associates 14, L... is at least $66.2 Milion dollars as of 4 November 2019. Enterprise L owns over 935,000 units of Oyster Point Pharma Inc stock worth over $66,185,456 and over the last 5 years Enterprise sold OYST stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Enterprise L OYST stock SEC Form 4 insiders trading

Enterprise has made over 1 trades of the Oyster Point Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Enterprise bought 935,000 units of OYST stock worth $14,960,000 on 4 November 2019.

The largest trade Enterprise's ever made was buying 935,000 units of Oyster Point Pharma Inc stock on 4 November 2019 worth over $14,960,000. On average, Enterprise trades about 935,000 units every 0 days since 2019. As of 4 November 2019 Enterprise still owns at least 5,925,287 units of Oyster Point Pharma Inc stock.

You can see the complete history of Enterprise L stock trades at the bottom of the page.

Insiders trading at Oyster Point Pharma Inc

Over the last 5 years, insiders at Oyster Point Pharma Inc have traded over $24,486,000 worth of Oyster Point Pharma Inc stock and bought 3,552,871 units worth $59,028,668 . The most active insiders traders include Ali Behbahani, Venture Capital Vi, L.P.Ver... a Clare Ozawa. On average, Oyster Point Pharma Inc executives and independent directors trade stock every 27 days with the average trade being worth of $2,204,444. The most recent stock trade was executed by Daniel Lochner on 1 November 2021, trading 8,590 units of OYST stock currently worth $98,871.

What does Oyster Point Pharma Inc do?

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.

Complete history of Enterprise L stock trades at Oyster Point Pharma Inc

Oyster Point Pharma Inc executives and stock owners

Oyster Point Pharma Inc executives and other stock owners filed with the SEC include:

• Jeffrey Nau,
  President, Chief Executive Officer, Director
• John Snisarenko,
  Chief Commercial Officer
• Daniel Lochner,
  Chief Financial Officer
• Dr. Jeffrey Nau Ph.D., MMS,
  Pres, CEO & Director
• Daniel Lochner M.B.A.,
  Chief Financial Officer
• John Snisarenko M.B.A.,
  Chief Commercial Officer
• Mark Murray,
  Director
• Ali Behbahani,
  Chairman of the Board
• Benjamin Tsai,
  Independent Director
• Aimee Weisner,
  Independent Director
• William Link,
  Independent Director
• Clare Ozawa,
  Independent Director
• Tim McCarthy,
  IR Contact Officer
• Michael Atieh,
  Director
• Dr. Marian Macsai M.D.,
  Chief Medical Officer of Medical Affairs
• Loni Da Silva M.S.,
  Sr. VP of Regulatory Affairs
• Raegan A. McClain CCEP, J.D., L.L.M.,
  Chief Compliance Officer
• Barry Rosenfeld J.D.,
  Sr. VP & Gen. Counsel
• Dr. Eric Carlson Ph.D.,
  Chief Scientific Officer
• George Donato M.B.A.,
  Sr. VP of CMC & Operations
• Ventures, Llc Vida,
  10% owner
• Point Pharma I, Llc Oyster,
  10% owner
• Vision Llckkr Healthcare St...,
  
• Gp Iv, L.L.C.Inv Opps Iv, L...,
  
• Michael Ackermann,
  Director
• Perkins Caufield & Byers Xi...,
  
• Venture Capital Vi, L.P.Ver...,
  
• Fund Holdings L.P.Kravis He...,
  
• George Christopher Eliades,
  Director
• Donald J Santel,
  Director
• Enterprise Associates 14, L...,